Many neurodegenerative diseases are characterized by the accumulation of amyloid fibers in the brain, which can occur when a protein misfolds into an extended -sheet conformation. The nucleation of these -sheet aggregates is of particular interest, not only because it is the rate-determining step toward fiber formation but also because early, soluble aggregate species may be the cytotoxic entities in many diseases. In the case of the prion peptide H1 (residues 109 -122 of the prion protein) stable amyloid fibers form only after the -strands of the peptide have adopted their equilibrium antiparallel -sheet configuration with residue 117 in register across all strands. In this article, we present the kinetic details of the realignment of these -strands from their fastformed nonequilibrium structure, which has no regular register of the strands, into the more ordered -sheets capable of aggregating into stable fibers. This process is likely the nucleating step toward the formation of stable fibers. Isotope-edited IR spectroscopy is used to monitor the alignment of the -strands by the introduction of a 13 C-labeled carbonyl at residue 117. Nonexponential kinetics is observed, with a complex dependence on concentration. The results are consistent with a mechanism in which the -sheet realigns by both the repeated detachment and annealing of strands in solution and reptation of polypeptide strands within an aggregate.IR spectroscopy ͉ peptide aggregation ͉ isotope-edited ͉ prion peptide ͉ amyloid fiber T he misfolding of proteins into a -sheet configuration and the subsequent aggregation of these -sheets is associated with many neurological disorders, including Alzheimer's, Huntington's, and Creutzfeldt-Jakob disease (1). These diseases are associated with the presence of large amyloid plaques, which contain fibrous aggregates of protein. Several detailed models for the mechanism of amyloid growth have been proposed, but all involve a conformational change in the protein that leads to the formation of soluble oligomers, which eventually nucleate the growth of larger fibers. With several diseases, including Alzheimer's and Parkinson's, the oligomeric intermediates may be the primary cytotoxic species (2-4).The soluble oligomeric intermediates are difficult to isolate and, because of their large size and dynamic nature, difficult to characterize with traditional biophysical techniques. For these reasons, many studies aimed at studying the aggregation process use small peptides, derived from full-length proteins of interest, which also show amyloidogenic behavior. Among the peptides studied extensively include the NFGAIL sequence from the islet amyloid polypeptide (5-7), fragments of the prion protein that include the AGAAAAGA amyloidogenic region (8-12), and many different fragments of the Alzheimer's A peptide (13)(14)(15)(16)(17)(18). In simulations of these peptides, ensembles of -sheet oligomers are initially formed, including species that have a non-native hydrogen-bonding registry or mix parallel and ant...